Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir and sofosbuvir for genotype 1 hepatitis C in decompensated cirrhosis
jRCTs051180003Completed
- Sponsor
- Funding from patient
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ledipasvir and sofosbuvir in hepatitis C virus infection, sponsored by Funding from patient. Primary endpoints: Serious adverse events occurrence rate and Sustained virological response at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
ledipasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on jRCTs051180003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180003.